Go To Market Consulting Inc. And Debiopharm Group Collaborate To Identify Early Stage In-licensing Opportunities On The US West Coast
LAUSANNE, Switzerland and SAN FRANCISCO, September 5, 2013 /PRNewswire/ --
Go To Market Consulting Inc. (Go To Market), a San Francisco headquartered business development representation and marketing services life sciences consulting firm, and Debiopharm Group ™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, have entered into an alliance to identify and scout West Coast companies, research institutes and/or individual investigators with in-licensing opportunities, including new compounds, products and/or technologies in oncology, auto-immune, infectious disease and metabolic conditions. Go To Market will collaborate with Debiopharm's existing in-house scouting team for first in-class opportunities for small molecule, antibody and peptide based product candidates.
In recognition of the depth and breadth of life science innovation in the West and in particular, the San Francisco Bay area, known for its culture of innovation, Debiopharm has selected Go To Market to strengthen its local activity in the region. Go To Market will work with Debiopharm's experienced scouting team to further increase the company's accessibility to in-licensing opportunities. David Deperthes, Vice President, Business Development & Licensing at Debiopharm said: "We have selected Go To Market because of their strength and understanding in the life sciences product development area. Their successful presence on the West Coast is a major asset to our search for new molecules. With this partnership we are deepening our commitment to finding the most promising drugs to develop for patients."
Maria Chiam, Founder of Go To Market added: "the West Coast is a rich area in science innovation. Debiopharm's track record of investing into and collaborating with early stage biopharmaceutical programs make it a choice partner for researchers and organizations wanting to move their preclinical programs into clinical development. Go To Market Consulting is delighted to work with Debiopharm to bring next generation therapeutics and diagnostic and personalized medicine initiatives to the market."About Go To Market Consulting Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts